KEYNOTE-867: pembrolizumab adds toxicity without improving outcomes after lung SBRT
In 448 patients with unresected early-stage NSCLC, pembrolizumab added to SBRT did not improve event-free survival but substantially increased severe toxicity.
In 448 patients with unresected early-stage NSCLC, pembrolizumab added to SBRT did not improve event-free survival but substantially increased severe toxicity.
A self-supervised model detected clinical pelvic MRI anomalies with AUC 0.95, but missed all five hydrogel spacers and lacked downstream clinical validation.
Across 62 studies and 3,278 patients, observed jaw osteoradionecrosis incidence after reirradiation was 3.6%, with substantial uncertainty across cohorts.
In a constrained phantom target, robust optimization reduced worst-case dose loss but increased minimum LET loss from 11.7% to 16.7%.
Before mask fabrication, 44% of 39 head and neck cancer patients screened positive for clinically meaningful anxiety; screening took a median 3.6 minutes.
In 378 prostate SABR patients, rectal spacer use was associated with lower one-year grade ≥1 gastrointestinal toxicity after adjustment (OR 0.31).
The randomized SwallPEG trial found no significant six-month swallowing quality-of-life difference between prophylactic and reactive gastrostomy, with early closure limiting certainty.
In 37 patients receiving preoperative spatially fractionated RT, major wound complications occurred in 37.5% with protons versus 38.1% with photons.
Within 41 lung cancer patients, lower thoracic lymph nodes moved 5.2 versus 3.3 mm cranio-caudally, challenging uniform internal margins.
In external validation, combined MRI–endoscopy AI predicted rectal cancer pathological complete response with AUC 0.818, but precision was only 37.8%.
In 22 paired lattice plans, helical tomotherapy reduced valley-to-peak dose ratios and low-dose spill versus VMAT but required 2.5-fold longer beam-on time.
Updated ASTRO guidance favors moderate hypofractionation for all risk groups, supports five-fraction SBRT in selected patients, and restricts ultrahypofractionated pelvic nodal RT to trials.
In 60 patients with postradiation skull-base osteoradionecrosis, ultrasound-guided flap reconstruction showed approximately 93–95% survival, with prolonged surgery associated with necrosis.
In 15 prostate nodal recurrence cases, IMPT maintained target coverage while substantially reducing kidney, bowel and integral dose compared with VMAT.
In 33 right-sided breast RT patients, larger target dimensions correlated with higher ipsilateral lung and cardiac doses, but proposed thresholds remain unvalidated.